A steroid injection costs $200 in a private physician's office. The same injection, at a hospital-owned outpatient site, costs $600. Same drug, same procedure, different billing address. That price gap is not a quirk. It is the documented arithmetic of consolidation, and it scales: approximately 1,200 hospital mergers over the past 2 decades have pushed prices up as much as 30%, according to research cited by health economist Ezekiel Emanuel, with minimal efficiency or quality gains to show for it.
So when Missouri's House advanced a bill on April 6, 2026, granting antitrust immunity to University of Missouri Health Care for acquiring hospitals across 25 rural counties, the correct response is not applause. The bill contains no rate transparency requirements, no service maintenance obligations, no post-acquisition pricing oversight. None. It hands a single health system market dominance and asks nothing in return.
The Evidence Does Not Support Blank-Check Immunity
Certificate-of-public-advantage frameworks exist precisely because policymakers recognized that sometimes consolidation in thin rural markets is unavoidable. Virginia, Tennessee, and Indiana all use them. The mechanism is not the problem. The mechanism paired with zero accountability conditions is the problem. North Carolina repealed its oversight requirements in 2025 and watched an insurer sever ties and a national chain move in. That is not a cautionary anecdote. That is a controlled experiment with a documented outcome.
Washington state ran the opposite experiment. House Bill 2548, enacted March 25, 2026 and effective June 11, expands state review to cover private equity-backed deals, management services contracts, and nonprofit-to-for-profit conversions. It removes the $10 million revenue threshold for out-of-state entities. The law does not block consolidation. It requires visibility into who owns what and what they plan to do with it. That is a reasonable minimum standard, not regulatory overreach.
I will grant the consolidation advocates one fair point: rural hospitals are genuinely fragile, and some mergers prevent closures that would leave patients with no care at all. Stability matters. But stability purchased by eliminating price accountability is not a health policy win. It is a transfer of negotiating power from patients and insurers to a single dominant system, permanently.
Federal Enforcement Has Abdicated, and States Are Filling the Gap Unevenly
The federal antitrust apparatus is under-resourced and slow. The FTC and DOJ have challenged some mergers, but "all-or-nothing" contracting, where dominant hospital systems force insurers to include all their facilities or none, continues largely unchecked. CMS projects health care spending will exceed 20% of U.S. GDP by 2033. Hospitals account for one-third of all care delivery costs and are, as Brian Blase has noted, the fastest-growing part of the problem.
Here is the tension I cannot fully resolve: site-neutral payment reform, which would eliminate the billing disparity between hospital-owned and independent sites, is the most direct federal lever available. But hospitals have legitimate concerns that rapid implementation would destabilize finances at institutions already operating on thin margins. The transition risk is real. That does not make the reform wrong. It makes the timeline a genuine policy question rather than a reason to shelve it.
What is not a genuine question is whether Missouri's model should spread. Antitrust immunity without pricing conditions, service guarantees, or reporting requirements is not rural health policy. It is market capture dressed in public interest language. Congress should establish a federal floor requiring any state-granted antitrust immunity to include mandatory price transparency and service maintenance terms. Washington showed it can be done. Missouri showed what happens when it isn't.
